A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Laekna Limited
Ohio State University Comprehensive Cancer Center
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)